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Targeting out-of-hospital 
cardiac arrest: the effect 




Introduction. Heparin administration during cardiopulmonary resuscitation (CPR) may prevent activation of coagulation after 
successful resuscitation for out-of-hospital cardiac arrest (OHCA). We hypothesize that such an approach is not associated 
with an increased rate of bleeding, but it has not been evaluated. We performed a pilot randomized clinical study assessing 
the safety of intra-arrest heparin administration in OHCA patients with suspected acute myocardial infarction (AMI) and its 
impact on their prognosis. 
Materials and Methods.  OHCA patients were randomized during CPR to 10 000 units of intra-arrest intravenous heparin (Group 
H) or to treatment without heparin (Group C). The occurrence of major bleeding and the presence of a favourable neurological 
result 3 months after OHCA, were analyzed.
Results. Out of 88 randomized patients, AMI was subsequently confirmed in 63 of them (71.6 %). There were 30 patients in 
group H and 33 in group C. No major bleeding event was observed in either group. Return of spontaneous circulation (ROSC, 
Group H: 40.0%, Group C: 45.4%, p=0.662) and a good neurological result 3 months after OHCA (Group H: 6.7 %, Group C: 
9.1 %, p=0.921) did not differ between groups.
Conclusions. Intravenous administration of 10 000 units of heparin during CPR for OHCA in patients with supposed AMI was safe. 
We did not find any improvement in prognosis for our sample of limited size. Though the procedure proved safe, we recommend 
postponing the administration of heparin until ROSC, assessment of  clinical state and  recording of a  twelve-lead ECG.
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Introduction
Out-of-hospital cardiac arrest (OHCA) 
is a critical condition with an uncertain 
prognosis. Even if  effective cardiopul-
monary resuscitation (CPR) is started, a 
number of complex pathophysiological 
mechanisms are activated during the 
arrest and after it, resulting in the devel-
opment of  ischemia-reperfusion injury 
and  post-cardiac arrest syndrome. (1) 
One of these processes is systemic 
coagulation activation with subsequent 
fibrin formation. In conjunction with 
other processes, such as activation 
of leucocytes, endothelial dysfunction 
and increased blood viscosity, this can 
lead to microcirculatory dysfunction 
and no-reflow phenomenon. (2-4) One 
of the theoretical possibilities of how to 
stop the spiral of  ischemia-reperfusion 
injuries is the preventive administration 
of a thrombolytic and/or anticoagulant 
agent during CPR. Moreover, in the 
case of a cardiac aetiology of OHCA, 
the primary thrombotic episode in the 
coronary or pulmonary artery may also 
be a potential target of this therapy.
While systemic thrombolysis during 
OHCA has been studied, to the best 
of  our  knowledge, there has been 
no published clinical trial evaluating 
the preventive impact of sole heparin 
administration during CPR. (3,5) We 
hypothesize that such an approach 
is safe and not associated with an 
increased rate of bleeding. However, 
this treatment has not been included in 
the CPR guidelines. (6,7) Thus, it should 
be assessed by a clinical study. 
Therefore, we decided to perform a pilot 
randomized clinical study to assess the 
safety of administering non-fraction-
ated heparin during CPR for OHCA 
to patients presumed to have  acute 
myocardial infarction (AMI) and also to 
analyze its impact on their prognosis.
Materials and Methods
The clinical study was carried out in 
accordance with the Declaration of Hel-
sinki and its realization was approved 
by the ethics committee. Informed 
consent was waived for the clinical 
condition of the patients with cardiac 
arrest. The study was the first part of the 
project  T-ARREST working group (Tar-
geting Out-of-Hospital Cardiac Arrest). 
Patients treated by the City of Prague 
Emergency Medical Service were 
included. The protocol of the study was 
carried out during emergency pre-hos-
pital care and contained two decision-
making moments (figure 1). In the first 
stage, the attending physician of the 
Emergency Medical Service decided, 
usually immediately upon   arrival,  if the 
patient having an OHCA is a suitable 
prospective candidate for randomiza-
tion. The criteria for including or not 
including the patients for randomisation 
are summarized in table 1. The diagno-
sis of acute myocardial infarction, as a 
supposed cause of OHCA, was done 
on the basis of the following conditions: 
1. the absence of signs of bleeding 
and trauma and 2. the collapse was 
preceded by the sudden onset of chest 
pain (or another type of sudden pain 
as left or right arm, abdominal or neck 
pain) and/or with dyspnoea or 3. the 
patient exhibited any prodromal symp-
toms before collapse and/or 4. known 
history of coronary artery disease.
CPR was always performed in accord-
ance with European resuscitation 
council guidelines. After completing 
all routine procedures specified by 
standard protocols (continuous ECG 
monitoring, endotracheal intubation, 
venous access, initial defibrillation if 
indicated, continuous monitoring of 
peripheral oxygen saturation SpO2 and 
end tidal CO2 (EtCO2), the patients 
were randomized (by random num-
bers generator) during ongoing CPR 
to a intravenous bolus administration 
of non-fractionated heparin (Heparin, 
Leciva, inj. sol.) in a dose of 10 000 units 
(Group H) or to continuing standard 
resuscitation without the administra-
tion of heparin during the procedure 
(Group C). For both groups,  CPR was 
performed for at least 30 minutes or 
until return of spontaneous circulation 
(ROSC). In the case of ROSC,  patients 
were transported to hospitals where the 
method of direct percutaneous coronary 
intervention was available. Subsequent 
in-hospital therapy was standard and 
not influenced by the study protocol. 
Clinical course was followed up accord-
ing to the Utstein protocol. Finally, the 
diagnosis of acute myocardial infarc-
tion was reassessed for all patients 
(clinically during hospitalization or by 
post-mortem examination).
The patients whose spontaneous cir-
culation returned before completing all 
monitoring and therapeutic procedures 
and the patients who failed to undergo 
all the above mentioned procedures 
were not randomized. These patients 
were not followed up.
Artificial ventilation during and after CPR 
was carried out in a routine way with the 
respiration rate aproximately14/min, the 
tidal volumes 7-10 ml.kg-1 and oxy-
gen inspiratory fraction 1.0 (MEDUMAT 
Standard, Weinmann medical technol-
ogy, Hamburg, Deutschland). Monitor-
ing of EtCO2 was performed using the 
mainstream technique (Zoll’s M Series 
defibrillator, Zoll Medical Corporation, 
Chelmsford, MA, USA). Monitoring of 
ECG and  electric impulse therapy was 
also ensured by the Zoll apparatus and 
all measurements were saved on the 
memory card of the apparatus pro-
viding precise feedback and assess-
ment of the resuscitation. Midazolam 
combined with fentanyl or sufentanyl 
were used for analgesia and sedation 
of patients. Pipecuronium was used 
for muscle relaxation, if needed. All 
patients who achieved  ROSC were 
subsequently administered lysine sali-
cylate intravenously. Patients in Group 
C were not given heparin in the pre-
hospital stage of treatment even after 
achieving ROSC.
Endpoints
The primary endpoint was the presence 
of major bleeding in the pre-hospital 
stage of treatment or during the first 
48 hours of hospitalization, as a safety 
measure. Major bleeding was defined 
as a decrease in haemoglobin levels 
of >20 g.l-1, need for transfusion of 
>2 units of blood, need for corrective 
surgery, intracranial or retroperitoneal 
haemorrhage, or any combination of 
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system. (9) Categories 1 and 2 were 
considered  a favourable result. 
Statistical analysis
The values of monitored parameters 
were expressed as average values ± 
standard deviation (SD) or as median 
(minimal – maximal value) or by per-
centage. The differences between 
unpaired groups in case of alternative 
variables were compared by Pearson’s 
chi-square test and in case of continual 
variables by Student’s t-test. The differ-
ences between groups with non-normal 
data distribution were compared by Wil-
coxon rank sum test. The statistics were 
processed using Microsoft Excel 2007 
programme (Microsoft, Redmond, WA, 
USA) and JMP 3.2 statistical software 
(SAS Institute, Cary, NC, USA). P value 
< 0.05 was considered statistically sig-
nificant.
Results
From January 2004 till December 2006 
there were 141 prospective candidates 
chosen for randomization. 88 of them 
(62.4 %) were randomized. The remain-
ing 53 patients either achieved ROSC 
before meeting technical conditions 
for randomization or it was not pos-
sible to ensure reliably all monitoring 
procedures required by the protocol 
and preceding the randomization (most 
often reliable monitoring of EtCO2 or 
oxygen saturation).
 AMI was subsequently confirmed in 
63 out of 88 randomized patients (71.6 
%). In the group of randomized patients 
who had another cause  of OHCA other 
than AMI (as confirmed afterwards), 11 
were given heparin during  CPR and 
14 patients were not. Major bleeding 
(gastrointestinal) was observed at post-
mortem examination in one patient who 
had been given heparin. Clinical caus-
es of  arrest, the primary success rate 
of  CPR and the neurological result and 
mortality during the three months after 
the arrest are presented in table 2. 
In the group of randomized patients with 
confirmed AMI, 30 were randomized to 
Group H and 33 patients to Group C. 
These patients were subject to detailed 
analysis. Basic demographic data, the 
Table 1. Inclusion and exclusion criteria for randomization.
INCLUSION CRITERIA FOR RANDOMIZATION*
 out-of-hospital cardiac arrest
 supposed aetiology of  acute myocardial infarction
 starting  cardiopulmonary resuscitation
EXCLUSION CRITERIA FOR RANDOMIZATION**
 possible or certain traumatic, bleeding or other non-infarction aetiology of  cardiac arrest
 absence of a physician at  the emergency medical service at the start of  cardiopulmonary 
resuscitation
 pre-defined status not to intubate and/or  resuscitate
Note: *…must meet all criteria, **…must not meet any of the criteria
Table 2. Clinical causes of OHCA, ROSC rate,  three-month mortality and the 
neurological result in patients with other aetiology of OHCA, other than AMI.
OHCA, out-of-hospital cardiac arrest; AMI, acute myocardial infarction; ROSC, 
return of  spontaneous circulation; CPC, cerebral performance category.
GROUP H GROUP C p
Number of patients (n) 11 14
Clinical cause of the arrest
          Pulmonary oedema (n (%)) 4 (36.4) 4 (28.6) 0.987
          Pulmonary embolism (n (%)) 4 (36.4) 3 (21.,4) 0.704
          Pulmonary disease (n (%)) 3 (27.2) 5 (35.7) 0.984
          Other (n (%)) 0 2 (14.3) 0.572
Achieved ROSC (n (%)) 6 (54.5) 6 (42.3) 0.839
Three-month mortality (n (%)) 6 (54.5) 10 (71.4) 0.650
CPC 1 or 2 after 3 months (n (%)) 2 (18.2) 1 (7.1) 0.820
CPC 3 or 4 after 3 months (n (%)) 3 (27.3) 3 (21.4) 0.897
OHCA, out-of-hospital cardiac arrest; AMI, acute myocardial infarction; ROSC, return of 
spontaneous circulation; CPC,cerebral performance category.
these events diagnosed clinically or 
by post-mortem examination. (8) The 
secondary endpoints were mortality 
rate and recovering with a favourable 
neurological result 3 months after car-
diac arrest. The neurological result was 
assessed according to the Cerebral 
Performance Category (CPC) marking 
 27www.signavitae.com
initial rhythm and parameters describ-
ing  cardiopulmonary resuscitation are 
presented in table 3. Ventricular fibrilla-
tion, as an initial rhythm, was found in 
the majority of  patients in both groups, 
all remaining patients had asystole. 
Only a minority of  patients presented 
prodromal pre-arrest symptoms, name-
ly chest pain (group H: 20.0 %, group 
C: 21.2 %, p=0.905), nausea (group H: 
13.3 %, group C: 12.1 %, p=0.885) and 
dyspnoea (group H: 6.7 %, group C: 
9.1 %, p=0.722). AMI was diagnosed 
in most of them as a probable cause 
(in Group H: 60.0 %, in Group C: 57.6 
%, p=0.735).
Major bleeding was not observed in any 
patient in Group H and in Group C.
There were no statistical differences 
between groups in regard to having a 
favourable neurological result and mor-
tality 3 months after the OHCA (table 
4). In the subgroup of  patients who 
achieved  ROSC in the pre-hospital 
stage of treatment, a favourable neuro-
logical result 3 months after the OHCA 
was reached with  comparable frequen-
cy as well (Group H: 16.7 %, Group C: 
20.0 %, p=0.825).
Discussion
The main finding of our study is that the 
administration of heparin during  car-
diopulmonary resuscitation for OHCA 
as a consequence of  acute myocar-
dial infarction is a safe procedure, not 
associated with an  increased number 
of major bleeding events. Its impact 
on  long-term prognosis is not clear. 
Out-of-hospital cardiac arrest is an 
extremely serious medical event. Only 
approximately 11% of patients survive 
to be discharged from hospital. (10,11) 
One of the procedures that may possi-
bly improve the clinical results of resus-
citated OHCA patients is very  early 
pharmacological intervention during 
CPR, potentially having an influence on 
the cause of OHCA and also on sub-
sequent post-resuscitation processes. 
Some mechanisms of  ischemia-reper-
fusion injury are activated as early as 
during CPR. Significant activation of 
thrombocytes and coagulation cas-
cades without corresponding increase 
Table 3. Demographic data,  initial rhythm and  characteristics of  CPR.
GROUP H GROUP C p
Number of patients in the 
group (n)
30 33
Men in the group (n (%)) 25 (83.3) 30 (90.1) 0.367
Age (median (min-max)) 65.0 (27-85) 64.0 (20-82) 0.934
Estimated body weight 
(kg±SD)
84 ± 13 89 ± 16 0.181
Any bystander CPR attempt (n 
(%))
12 (40.0) 13 (39.4) 0.961
Any symptoms preceding 
OHCA (median (min-max)
12 (40.0) 14 (42.4) 0.845
VF as the initial rhythm (n (%)) 27 (90.0) 30 (90.1) 0.902
Time from collapse to any  
resuscitation attempt (min±SD)
4.3±3.1 4.5±3.4 0.807
Time from collapse to ROSC/
end of CPR (min±SD)
38 ± 22 29 ± 12 0.046
Cumulative defibrillation ener-
gy in 








Cumulative epinephrine dose 
(mg, 
median (min.max))
4.0 (0-14) 4.0 (0-13) 0.787
Achieved ROSC (n (%)) 12 (40.0) 15 (45.4) 0.662
Recurrence of cardiac arrest 
during 
transport (n (%))
2 (6.7) 3 (6.1) 0.722
Ongoing CPR on arrival at  
hospital 
(n (%))
1 (7.5) 1 (12.5) 0.945
CPR, cardiopulmonary resuscitation; max, maximal value; min, minimal value; ROSC, return 
of  spontaneous circulation; OHCA, out-of-hospital cardiac arrest; SD, standard deviation; 
VF, ventricular fibrillation.
Table 4. Three-month mortality and patients’  neurological results.
CPC, cerebral performance category.
GROUP H GROUP C p
Three-month mortality (n (%)) 26 (86.6) 26 (78.8) 0.411
Achieved CPC 1 or 2 after 3 mon-
ths (n (%))
2 (6.7) 3 (9.1) 0.921
Achieved CPC 3 or 4 after 3 mon-
ths (n (%))
2 (6.7) 4 (12.1) 0.885
28 www.signavitae.com
of fibrinolytic activity are also among 
them. (12) This considerable imbal-
ance favouring blood clotting may 
lead to  microcirculation dysfunction 
based both on the vasoactive basis and 
microthrombi formation in tissues. This 
was described especially in the brain 
and the impairment of coagulation 
activity in the microvascular compart-
ment has been considered to be one of 
the main conditions leading to the cer-
ebral no-reflow phenomenon. (3) The 
degree of  no-reflow probably trans-
lates into the neurological outcome. A 
decreased possibility of spontaneous 
reperfusion of the thrombotic closure 
of the coronary artery may also play a 
role. Observational studies assessing 
the importance of echocardiography 
during prolonged resuscitation showed 
that the presence of a spontaneous 
echo contrast during CPR was con-
nected with a worse prognosis. (13-15) 
All of these lead to the reduction of oxy-
gen supplies in tissues and contribute 
to the development of the post-cardiac 
arrest syndrome and subsequent organ 
dysfunctions. (2,16) In theory, this unfa-
vourable state may be positively modi-
fied by antithrombotic treatment. 
The isolated effect of the antiaggregant 
treatment on the processes during and 
after cardiac arrest has been studied 
only to a very limited extent. (17-22) In 
general, these are experimental recep-
tor studies. No trials evaluating the 
safety and/or clinical effectiveness  of 
antiaggregants administered during 
cardiac arrest have been published. 
With regards to the boom of new and 
very effective antiaggregants, with 
the possibility of intravenous admin-
istration, there is much space left for 
research into  their effect  in patients 
with  cardiac arrest.(23)
The attention of researches has been 
recently focused  on  the study of the 
effect of  systemic thrombolysis given 
during CPR on patients´ prognosis. 
(24-30) Bottiger et al. have carried out 
an extensive multicentric clinical trial 
TROICA (Thrombolysis Using Tenect-
eplase in Cardiac Arrest). They rand-
omized 1050 patients with OHCA of sup-
posed cardiac aetiology to  the adminis-
Figure 1. Study protocol schedule.
CPR, cardiopulmonary resuscitation; EMS, emergency medical service; OHCA, 
out-of-hospital cardiac arrest; ROSC, return of  spontaneous circulation
tration of tenecteplase bolus or placebo 
during CPR. The authors did not find 
any difference in  thirty-day survival (14.7 
versus 17.0 %, p=0,36). (27) 
The only bleeding event found  in the 
study was an incidence of intracranial 
bleeding. It was increased in the ten-
ecteplase group (2.7 versus 0.4 %, 
p=0.006). However, in some patients 
the bleeding was a cause of cardiac 
arrest and most of the patients were 
asymptomatic. Since indications for cra-
nial computer scanning were not prede-
fined,  detection bias cannot be ruled 
out. A metaanalysis of small studies 
and case reports revealed  data about 
the safety of the administration of a 
thrombolytic agent during CPR. (31) 
We decided to evaluate the safety and 
effect of heparin administered during 
CPR for  several reasons. Firstly, the 
influence of heparin on the success rate 
of CPR has been studied insufficiently 
in a similar way as the effect of  antiag-
gregant treatment. Only certain positive 
results were observed in animal experi-
ments. (32,33) In clinical practice, there 
are only studies combining heparin 
with  system thrombolysis and a case 
reportconcerning the administration of 
heparin. (27,34) Secondly, it is important 
that ambiguous results of thrombolytic 
studies do not automatically disqualify 
a possible profit from the administration 
of heparin. The effect of heparin on the 
coagulation and fibrinolytic system is 
different from the effect of thrombolysis 
and from the point of view of patho-
physiology it may be used especially 
as intracardiac thrombosis prevention 
during  arrest and microcirculation dys-
function. (34) Thirdly, the administration 
of heparin is very simple and it is an inex-
pensive drug. Being a  pilot study, we 
mainly focused on the safety of such an 
approach, expressed by the incidence 
of  major bleeding events.
The first important point is the diagnosis 
of a possible cardiac cause of OHCA 
itself. It is necessary to disqualify any 
traumatic cause and/or bleeding. The 
information about the medical history 
of the patients and about any prodro-
mal symptoms that directly preceded 
OHCA (if there were any at all) is not 
always available. Usually, it is neces-
sary to make a diagnosis based on 
the result of a rapid examination of an 
unconscious patient with  cardiac arrest 
and to use the process of elimination. 
Acute myocardial infarction is the cause 
of OHCA in one half to two thirds of 
all cases of OHCA after eliminating 
apparently non-cardiac causes, that is 
traumatic causes and/or bleeding etc. 
(35,36) The number of patients with AMI 
would be probably even higher after 
eliminating patients supposed to have 
pulmonary embolism. In our group, 
respecting the inclusion criteria, the 
diagnosis of  acute myocardial infarc-
tion was confirmed later in 71.6 % of 
cases. This relatively high confidence 
level of the initial diagnosis confirms 
the above mentioned observations and 
at the same time makes it possible in 
a relatively reliable way to identify the 
most suitable target group of patients 
with OHCA for  anti-thrombotic inter-
vention during CPR.
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The key finding of our study is that the 
use of heparin during CPR was not 
associated with an  increase in  major 
bleeding events during the pre-hospital 
and early in-hospital period. Even in 
those patients who did not reach ROSC 
in the field, no bleeding events, poten-
tially worsening the chance to achieve 
ROSC, were found. Therefore, we con-
sider the administration of unfraction-
ated heparin during CPR in  OHCA 
patients with presumed AMI  safe.
We did not observe any impact of 
heparin administration on the three-
month mortality and on the incidence 
of a good neurological outcome  in 
our study. There are several possible 
reasons for this finding: Is it a small 
number of patients in the study? Is it 
the absence of any effect of heparin, 
an unsuitable study design, an incor-
rect dosage of heparin or a choice of 
unsuitable endpoints? All of the above 
mentioned elements may influence the 
result. We are sure that more patients 
included would be beneficial, how-
ever, the outcome was not the primary 
endpoint. An optimal way would be to 
perform a double-blinded clinical study 
with a high number of randomized 
patients and  thoroughly defined pre-
hospital and hospital care, with heparin 
dosages in units/kg of body weight and 
a technical primary endpoint directly 
assessing the coagulation activity and 
the state of microcirculation. Neverthe-
less, such a study would be extremely 
demanding in regard to  financing, time 
and organization, especially in view 
of  the fact that the study concerns a 
pre-hospital intervention in patients with 
OHCA during CPR. 
The major limitation of the study is the 
sample size. It is not large enough to 
evaluate the impact of the study inter-
vention  on the neurological prognosis. 
However, the primary endpoint was a 
safety issue and because of absence of 
previous data about this topic, sample 
size was not possible to calculate.
In conclusion, the intravenous adminis-
tration of non-fractionated heparin in a 
dose of 10 000 units during CPR for  out-
of-hospital cardiac arrest in patients with 
supposed AMI was a safe procedure. 
We did not observe any improvement 
in  patients´ prognosis. Though the pro-
cedure proved safe, we recommend 
postponing the administration of heparin 
until the return of spontaneous circula-
tion, the assessment of  clinical state 
and the recording of a  twelve-lead ECG 
and until further specification of the diag-
nosis or of acute coronary syndrome or 
pulmonary embolism. Our pilot study 
presents more questions than answers. 
However, it is important from our point of 
view that the study proved the safety and 
simplicity of the procedure.
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